Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference

XENE 10.02.2024

Full Press ReleaseSEC FilingsOur XENE Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Xenon Outlines Key Corporate Milestone Opportunities for 2025
  • 01.07.2025 - Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.17.2025 - 8-K Current report
  • 12.19.2024 - 4 Statement of changes in beneficial ownership of securities
  • 12.18.2024 - 144 Report of proposed sale of securities

VANCOUVER, British ColumbiaandBOSTON,Oct. 02, 2024(GLOBE NEWSWIRE) --Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced its participation in the upcomingBofA Securities2024CNS Therapeutics Virtual Conferencetaking placeOctober 7, 2024.

Fireside Chat Presentation Details:
Date:Monday, October 7, 2024
Time:11:40 am Eastern Time
Webcast:Register here

A live webcast of the company presentation will be available on the “Investors” section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.

AboutXenon Pharmaceuticals Inc.

Xenon Pharmaceuticals(Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, our lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visitwww.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks ofXenon Pharmaceuticals Inc.in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:For Investors:Chad FugereVice President, Investor Relations(857) 675-7275investors@xenon-pharma.com

For Media:Colleen AlabisoSenior Vice President, Corporate Affairs(617) 671-9238media@xenon-pharma.com

Primary Logo

Source: Xenon Pharmaceuticals Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com